Targeting the Correct Population for Trials: A Post‐hoc Analysis of Trial of Solanezumab for Mild Dementia Due to Alzheimer’s disease

Ezzati, A., Petersen, K. K., Nallapu, B. T., Davatzikos, C., Wolk, D. A., Rabin, L., Habeck, C., Hall, C. B., & Lipton, R. B. (2022). Targeting the Correct Population for Trials: A Post‐hoc Analysis of Trial of Solanezumab for Mild Dementia Due to Alzheimer’s disease. Alzheimer’s & Dementia, 18(S10). Portico. https://doi.org/10.1002/alz.065995
Authors:
Ali Ezzati
Kellen K. Petersen
Bhargav Teja Nallapu
Christos Davatzikos
David A. Wolk
Laura A. Rabin
Christian Habeck
Charles B. Hall
Richard B. Lipton
Affiliated Authors:
Christian Habeck
Subjects:
Health Economics and Quality of Life Assessment (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1002/alz.065995
DOI:
10.1002/alz.065995
Journal:
Alzheimer's and Dementia
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: